Month: February 2021

Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patientsBeyond Air recently initiated a pilot study using LungFit™ GO for at-home self-administration of up to 250 ppm NO to treat refractory NTM pulmonary disease in adult patientsGARDEN CITY, N.Y., Feb. 16, 2021 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced a funding agreement with the Cystic Fibrosis Foundation to advance the clinical development...

-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development —-GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Dave Knop, Vice President of Process Development, and Jill Dolgin, PharmD, Executive Director of Patient Advocacy, will present at the 4th Annual Gene Therapy for Rare Disorders digital event taking place February 22-25, 2021.Dr. Knop will lead a pre-conference workshop, “Unifying Process & Analytical Development to Establish Robust, Scalable Gene Therapy Manufacturing Processes”...

VANCOUVER, British Columbia, Feb. 16, 2021 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2) (the “Company”) is pleased to announce that it has reached an agreement on 11th February 2021 to integrate the large, highly recognized Chinese Payment processing entity ALIPAY into RevoluPAY and upcoming white-label platforms. Final coding integration has already commenced and is expected to conclude by the 14th of March 2021.About ALIPAYALIPAY is a brand of Alibaba’s fintech affiliate Ant Group formerly known as Ant Financial. The group owns China’s most prominent digital payment platform Alipay, which serves approximately 1.3 billion users and 80 million merchants worldwide. Alipay maintains a 54% share and Tenpay 39% of the Chinese mobile-payments market by value. However, unlike competitor...

ROCKAWAY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that on Friday, February 12, 2021, the company received Section 510(k) clearance from the Unites States Food and Drug Administration (FDA) of the company’s submission to expand the label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17 years of age. gammaCore is now cleared for most forms of primary headache including the acute and preventive treatment of migraine in adolescents and adults, as well as the acute and preventive treatment of cluster headache in adults.Dr. Andrew Hershey, Endowed Chair and Director of Neurology at Cincinnati Children’s Medical Center and Professor of Pediatrics and Neurology at the University...

TORONTO, Feb. 16, 2021 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is pleased to announce that the trustees of ERES have declared the February 2021 monthly cash distribution of €0.00875 per Unit and Class B LP Unit (the “February Distribution”), being equivalent to €0.105 per Unit annualized. The distribution will be payable to holders of the Units and Class B LP Units (the “Unitholders”) of record on February 26, 2021, with payment on March 15, 2021.The Euro-denominated distribution will be paid in Canadian dollars based on the exchange rate on the date of payment (estimated C$0.01343 per Unit and Class B LP Unit). Registered Unitholders will be provided with an option to elect to receive such distribution in Euros rather than Canadian dollars. If no such election is made, registered...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES(Note: All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted.)TORONTO, Feb. 16, 2021 (GLOBE NEWSWIRE) — Fairfax India Holdings Corporation (“Fairfax India”) (TSX: FIH.U) announces that Seven Islands Shipping Limited (“Seven Islands”) has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India (“SEBI”) in connection with an initial public offering (the “IPO”).The IPO will mainly consist of a primary issuance of shares by Seven Islands and a secondary sale of shares by existing Seven Islands shareholders and Fairfax India. Seven Islands may raise up to INR 4,000 million (approximately $55 million at current exchange rates) in the IPO by issuing fresh equity shares. Details...

CHARLOTTESVILLE, Va., Feb. 16, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, today announced completion and topline data from the open-label, Phase 1b clinical trial of its novel, diffusion-enhancing therapeutic, trans sodium crocetinate (“TSC”), in hospitalized COVID-19 patients with confirmed hypoxemia, the most common cause of tissue hypoxia. The primary objective of the trial was to evaluate the safety and tolerability of TSC administered on a more frequent dosing regimen not previously tested in a clinical trial setting. Secondary endpoints included pharmacokinetic measurement of TSC levels after dosing, relative improvements in blood oxygen...

Top-line Data Anticipated by Year End 2021Enrollment Also Continues to Progress in Company’s Second Phase 3 Clinical Trial, SHIELD IIPETAH TIKVA, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that the 100th patient has been enrolled and randomized in the SHIELD I (Surgical site Hospital acquired Infection prEvention with Local D-plex) trial, the Company’s first of two Phase 3 clinical trials for its lead product candidate, D-PLEX100, for the prevention of post-abdominal surgery incisional infections (soft tissue).“Enrollment in our first Phase 3 clinical trial, SHIELD I, continues to progress as expected, and we are excited to have now enrolled...

ROCHESTER, Mich., Feb. 16, 2021 (GLOBE NEWSWIRE) — OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at the SVB Leerink 10th Annual Global Healthcare Conference being held virtually on February 22-26, 2021.OptimizeRx CEO, William Febbo, is scheduled to present on Thursday, February 25, at 5:00 p.m. Eastern time and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference.The presentation will be webcast live and available for replay here and via the investor relations section of the company’s website at www.optimizerx.com.Management will discuss the company’s recently reported record preliminary results for the fourth quarter and full year 2020. The company...